Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

被引：1

作者：

Rizk, Mohamed ^{[1
]}

Rizq, Ola ^{[2
]}

Oshima, Motohiko ^{[1
]}

Nakajima-Takagi, Yaeko ^{[1
]}

Koide, Shuhei ^{[1
]}

Saraya, Atsunori ^{[3
]}

Isshiki, Yusuke ^{[4
]}

Chiba, Tetsuhiro ^{[5
]}

Yamazaki, Satoshi ^{[6
]}

Ma, Anqi ^{[7
,8
]}

Jin, Jian ^{[7
,8
]}

Iwama, Atsushi ^{[1
]}

Mimura, Naoya ^{[9
]}

机构：

[1] Univ Tokyo, Inst Med Sci, Div Stem Cell & Mol Med, Ctr Stem Cell Biol & Regenerat Med, Tokyo, Japan

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[3] Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan

[4] Oami Municipal Hosp, Dept Hematol, Chiba, Japan

[5] Chiba Univ Hosp, Dept Gastroenterol, Chiba, Japan

[6] Univ Tokyo, Inst Med Sci, Div Stem Cell Biol, Ctr Stem Cell Biol & Regenerat Med, Tokyo, Japan

[7] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pharmacol Sci, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA

[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA

[9] Chiba Univ Hosp, Dept Transfus Med & Cell Therapy, Chiba, Japan

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122157

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4400

引用

页数：3

共 50 条

[1] Study of Novel Inhibitor of EZH2/PRC2 in Cancer Cells
Murashima, Akihiro
Shinjo, Keiko
Katsushima, Keisuke
Onuki, Tetsuo
Ito, Akihiro
Yoshida, Minoru
Kondo, Yutaka
CANCER SCIENCE, 2018, 109 : 1175 - 1175
[2] An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors
Bratkowski, Matthew
Yang, Xin
Liu, Xin
SCIENTIFIC REPORTS, 2018, 8
[3] An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors
Matthew Bratkowski
Xin Yang
Xin Liu
Scientific Reports, 8
[4] Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
Rizq, Ola
Mimura, Naoya
Oshima, Motohiko
Saraya, Atsunori
Koide, Shuhei
Kato, Yuko
Aoyama, Kazumasa
Nakajima-Takagi, Yaeko
Wang, Changshan
Chiba, Tetsuhiro
Ma, Anqi
Jin, Jian
Iseki, Tohru
Nakaseko, Chiaki
Iwama, Atsushi
CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4817 - 4830
[5] Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies
Kroeze, Leonie I.
Nikoloski, Gorica
da Silva-Coelho, Pedro
van Hoogen, Patricia
Stevens-Linders, Ellen
Kuiper, Roland P.
Schnittger, Susanne
Haferlach, Torsten
Pahl, Heike L.
van der Reijden, Bert A.
Jansen, Joop H.
BLOOD, 2012, 119 (05) : 1318 - 1319
[6] Cryptic RNA-binding by PRC2 components EZH2 and SUZ12
Betancur, Juan G.
Tomari, Yukihide
RNA BIOLOGY, 2015, 12 (09) : 959 - 965
[7] Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor
Scott, Mary T.
Korfi, Koorosh
Gallipoli, Paolo
Saffrey, Peter
Jorgensen, Heather
Cruz, Michelle
Hamilton, Ashley
Sinclair, Amy
Crossan, Andrew
Normant, Emmanuel
Balasubramanian, Vidya
Holyoake, Tessa L.
Vetrie, David
BLOOD, 2013, 122 (21)
[8] Identification of a possible therapeutic candidate for multiple myeloma based on dual inhibition of EZH1/EZH2
Nakagawa, Makoto
Fujita, Shuhei
Honma, Daisuke
Araki, Kazushi
Kitabayashi, Issay
CANCER RESEARCH, 2017, 77
[9] Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells
Lovorka Stojic
Zuzana Jasencakova
Carolina Prezioso
Alexandra Stützer
Beatrice Bodega
Diego Pasini
Rebecca Klingberg
Chiara Mozzetta
Raphael Margueron
Pier Lorenzo Puri
Dirk Schwarzer
Kristian Helin
Wolfgang Fischle
Valerio Orlando
Epigenetics & Chromatin, 4
[10] Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition
Sinha, Subarna
Thomas, Daniel
Yu, Linda
Gentles, Andrew J.
Jung, Namyoung
Corces-Zimmerman, M. Ryan
Chan, Steven M.
Reinisch, Andreas
Feinberg, Andrew P.
Dill, David L.
Majeti, Ravindra
BLOOD, 2015, 125 (02) : 316 - 326

← 1 2 3 4 5 →